Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan™ in Alzheimer's Disease

Myriad Genetics, Inc. (NASDAQ: MYGN) announced results of the Act-Earli-AD trial, an 18-month Phase 3 study of Flurizan (tarenflurbil) in patients with mild Alzheimer’s disease. The study did not achieve statistical significance on either of its primary endpoints — cognition and activities of daily living.

Source: Myriad Genetics